



Revisión de la literatura VIH & COVID

Jose R Arribas

Servicio Medicina Interna/Unidad de Enfermedades Infecciosas
Hospital Universitario La Paz. Madrid.
CIBERINFEC

COVID

1. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. *Cell* 2023;186(2):279-286.e8.
2. Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. *N Engl J Med* 2023;388(6):518-28.
3. Cao Z, Gao W, Bao H, et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. *N Engl J Med* 2023;388(5):406-17.
4. Perner A, Venkatesh B. Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia? *The Lancet* 2023;401(10387):1474-6

VIH

Prevención ITS

5. Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. *New England Journal of Medicine* 2023;388:1296-306.

Curación

6. Hsu J, Van Besien K, Glesby MJ, et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. *Cell* 2023 186:1115-1126.e8.
7. Climent N, Ambrosioni J, González T, et al. Immunological and virological findings in a patient with exceptional post-treatment control: a case report. *Lancet HIV* 2023;10(1):e42-51.

Enfermedades oportunistas

8. Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a global case series. *Lancet* 2023;S0140-6736(23)00273-8.
9. Palefsky JM, Lee JY, Jay N, et al. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. *N Engl J Med* 2022;386(24):2273-82.

Tratamiento antirretroviral

10. Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. *The Lancet HIV* 2023;10(1):e15-23.
11. Paton NI, Musaaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. *Lancet HIV* 2022;S2352-3018(22)00092-3.
12. Neesgaard B, Greenberg L, Miró JM, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. *The Lancet HIV* 2022;9:e474-85.
13. Surial B, Chammartin F, Damas J, et al. Impact of integrase inhibitors on cardiovascular disease events in people with HIV starting antiretroviral therapy. *Clin Infect Dis* 2023;ciad286.